

---

# VACCINE POINTS

---

“Vaccine Points” is a bi-monthly communication distributed by the Hawaii Department of Health to all participating Vaccines for Children (VFC) providers.

Test your vaccine knowledge.

Question:

Which of the following doses is/are considered “extra,” according to recommended vaccine schedules and/or ACIP recommendations, and therefore unnecessary? Select all that apply.

- a) RotaTeq® dose #3 at age 6 months  
(History: RotaTeq® dose #1 at age 2 months; RotaTeq® dose #2 at age 4 months)
- b) Rotarix® dose #3 at age 6 months  
(History: Rotarix® dose #1 at age 2 months; Rotarix® dose #2 at age 4 months)
- c) Menactra® booster at age 18 years  
(History: Menactra® dose #1 at age 12 years)
- d) Menveo® booster at age 18 years  
(History: Menveo® dose #1 at age 16 years)
- e) PedvaxHIB® dose #3 at age 6 months  
(History: PedvaxHIB® dose #1 at age 2 months; PedvaxHIB® dose #2 at age 4 months)
- f) ActHIB® dose #3 at age 6 months  
(History: ActHIB® dose #1 at age 2 months; ActHIB® dose #2 at age 4 months)

<http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf>  
Recommended Immunization Schedules for Persons Aged 0 Through 18 Years—United States, 2016

Source:

- RotaTeq® is administered as a 3-dose series at ages 2, 4, and 6 months.
- Rotarix® is administered as a 2-dose series at ages 2 and 4 months.
- Adolescents who receive a single dose of Menactra® or Menveo® at ages 11 through 12 year should receive a booster dose at age 16 years or later. If the first dose is administered at age 16 years or older, a booster dose is not needed.
- PedvaxHIB® is licensed as a 2-dose primary series for infants at ages 2 and 4 months, with a booster dose (dose #3) at age 12 months.
- ActHIB® is licensed as a 3-dose primary series for infants at ages 2, 4, and 6 months, with a booster dose (dose #4) at age 12 – 15 months.

Answer: b, d, and e

